Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Executive Summary
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research and Manufacturers of America told FDA in Feb. 14 comments.